Impact of Melatonin Supplementation on Glycemic Parameters in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis.

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2024-10-18 DOI:10.2174/0113816128345623241004080849

Reza Nejad Shahrokh Abadi, Mostafa Shahraki Jazinaki, Hossein Bahari, Mohammad Rashidmayvan, Mohammad Reza Amini, Mohsen Aliakbarian, Rozita Khodashahi, Mahsa Malekahmadi

{"title":"Impact of Melatonin Supplementation on Glycemic Parameters in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis.","authors":"Reza Nejad Shahrokh Abadi, Mostafa Shahraki Jazinaki, Hossein Bahari, Mohammad Rashidmayvan, Mohammad Reza Amini, Mohsen Aliakbarian, Rozita Khodashahi, Mahsa Malekahmadi","doi":"10.2174/0113816128345623241004080849","DOIUrl":null,"url":null,"abstract":"Background: Several previous studies indicated that melatonin supplementation may positively affect glycemic control in patients with diabetes. However, research on the influence of melatonin supplementation on glycemic parameters remains inconclusive. Therefore, this study aimed to assess the impacts of melatonin supplementation on glycemic parameters in type 2 diabetes by conducting a meta-analysis.Methods: PubMed/Medline, Scopus, and Web of Science were comprehensively searched until July 2024 to find eligible randomized clinical trials (RCTs). The overall effect sizes were estimated by using the randomeffect model and presented as weighted mean differences (WMD) with a 95% confidence interval (CI). Furthermore, the heterogeneity among the included trials was assessed by performing the Cochran Q test and interpreted based on the I² statistic.Results: Of the 1361 papers, eight eligible RCTs were included in this meta-analysis. Our findings indicated that melatonin supplementation significantly decreased fasting blood glucose (WMD = -12.65 mg/dl; 95% CI: -20.38, -4.92; P = 0.001), insulin (WMD = -2.30 μU/ml; 95% CI: -3.20, -1.40; P < 0.001), hemoglobin A1c (WMD = -0.79 %; 95% CI: -1.28, -0.29; P = 0.002), and HOMA-IR (WMD, -0.83; 95% CI: -1.59 to - 0.07; P = 0.03).Conclusion: According to the results of the current meta-analysis, persons with type 2 diabetes who supplement with melatonin had improved glycemic control. It looks that supplementing with melatonin at a dose exceeding 6 mg daily for over a period of 12 weeks may be more successful than other forms of intervention. Nevertheless, further research with larger sample sizes is necessary to draw definitive conclusions.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128345623241004080849","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Several previous studies indicated that melatonin supplementation may positively affect glycemic control in patients with diabetes. However, research on the influence of melatonin supplementation on glycemic parameters remains inconclusive. Therefore, this study aimed to assess the impacts of melatonin supplementation on glycemic parameters in type 2 diabetes by conducting a meta-analysis.

Methods: PubMed/Medline, Scopus, and Web of Science were comprehensively searched until July 2024 to find eligible randomized clinical trials (RCTs). The overall effect sizes were estimated by using the randomeffect model and presented as weighted mean differences (WMD) with a 95% confidence interval (CI). Furthermore, the heterogeneity among the included trials was assessed by performing the Cochran Q test and interpreted based on the I² statistic.

Results: Of the 1361 papers, eight eligible RCTs were included in this meta-analysis. Our findings indicated that melatonin supplementation significantly decreased fasting blood glucose (WMD = -12.65 mg/dl; 95% CI: -20.38, -4.92; P = 0.001), insulin (WMD = -2.30 μU/ml; 95% CI: -3.20, -1.40; P < 0.001), hemoglobin A1c (WMD = -0.79 %; 95% CI: -1.28, -0.29; P = 0.002), and HOMA-IR (WMD, -0.83; 95% CI: -1.59 to - 0.07; P = 0.03).

Conclusion: According to the results of the current meta-analysis, persons with type 2 diabetes who supplement with melatonin had improved glycemic control. It looks that supplementing with melatonin at a dose exceeding 6 mg daily for over a period of 12 weeks may be more successful than other forms of intervention. Nevertheless, further research with larger sample sizes is necessary to draw definitive conclusions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

补充褪黑素对 2 型糖尿病患者血糖参数的影响：系统回顾与元分析》。

背景：之前的一些研究表明，补充褪黑素可能会对糖尿病患者的血糖控制产生积极影响。然而，有关补充褪黑素对血糖参数影响的研究仍无定论。因此，本研究旨在通过荟萃分析评估补充褪黑素对 2 型糖尿病患者血糖指标的影响：方法：对截至 2024 年 7 月的 PubMed/Medline、Scopus 和 Web of Science 进行了全面检索，以找到符合条件的随机临床试验（RCT）。采用randomeffect模型估算总体效应大小，并以加权平均差（WMD）和95%置信区间（CI）的形式表示。此外，还通过 Cochran Q 检验评估了纳入试验之间的异质性，并根据 I² 统计量进行了解释：结果：在 1361 篇论文中，有 8 篇符合条件的 RCT 纳入了此次荟萃分析。我们的研究结果表明，补充褪黑素可显著降低空腹血糖（WMD = -12.65 mg/dl; 95% CI: -20.38, -4.92; P = 0.001）、胰岛素（WMD = -2.30 μU/ml; 95% CI: -3.20, -1.40; P < 0.001）、血红蛋白A1c（WMD = -0.79 %; 95% CI: -1.28, -0.29; P = 0.002）和HOMA-IR（WMD, -0.83; 95% CI: -1.59 to - 0.07; P = 0.03）：根据目前的荟萃分析结果，补充褪黑素的 2 型糖尿病患者的血糖控制有所改善。与其他形式的干预相比，每天补充超过 6 毫克褪黑素并持续 12 周的效果可能更好。不过，要想得出明确的结论，还需要进行样本量更大的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.